How to Buy krebsbio Shares on Fincept?
You can buy Krebs Biochemicals & Industries Limited shares on Different Brokers & Banks by creating an account and completing KYC verification online.
NSE: Krebs Biochemicals & Industries Limited Share Price Today, Share Analysis, Latest Updates & Insights | Fincept
Stay informed with the latest announcements for Krebsbio, including updates on board meetings and corporate actions.
Krebs Biochemicals & Industries Limited - https://krebsbiochem.com
Krebs Biochemicals & Industries Limited engages in the manufacture and sale of active pharmaceutical ingredients in India. The company develops biotech processes for application in medicine, agriculture, and industry. Its products include androstenedione, lovastatin, and simvastatin, which are used for anti-cholesterol and steroid intermediate applications. The company also develops various products, including amlodipine, cetirizine, orlistat, serratiopepetidase, telmisartan, and phenylephrine for anti-hypertension, anti-histamine, anti-obesity, anti-inflammatory, and cold and cough applications. In addition, it offers contract manufacturing services for large pharmaceutical and multinational companies. The company was incorporated in 1991 and is based in Visakhapatnam, India.
Krebs Biochemicals & Industries Limited Share Price Today
91.99
OPEN
94.65
HIGH
91.99
LOW
94.65
CLOSE
9 K
VOLUME
229 Cr
Market Cap
31428
Average Volume
Healthcare
Sector
NSI
Exchange
Krebs Biochemicals & Industries Limited Share Analysis & 2025 Insights
Investor Presentations
| Date | Description | Download |
|---|
SIP
Lumpsum
Invested Amount: ₹
Estimated Returns: ₹
Total Value: ₹
NSE: KREBSBIO Stock Actions
Company |
Symbol |
ISIN |
Subject |
Ex Date |
Face Value |
Broadcast Date |
|---|---|---|---|---|---|---|
Krebs Biochemicals and Industries Limited |
KREBSBIO |
INE268B01013 |
Annual General Meeting |
20 Sep 2023 |
10 |
N/A |
Krebs Biochemicals and Industries Limited |
KREBSBIO |
INE268B01013 |
Annual General Meeting |
15 Sep 2021 |
10 |
N/A |
Krebs Biochemicals and Industries Limited |
KREBSBIO |
INE268B01013 |
Annual General Meeting |
16 Sep 2020 |
10 |
N/A |
Krebs Biochemicals and Industries Limited |
KREBSBIO |
INE268B01013 |
Annual General Meeting |
13 Sep 2019 |
10 |
N/A |
Krebs Biochemicals and Industries Limited |
KREBSBIO |
INE268B01013 |
Rights 21:100 @ Premium Rs 76 Per Share |
31 Jan 2019 |
10 |
N/A |
NSE: KREBSBIO Recent Announcements
Symbol |
Date |
Description |
Industry |
|---|---|---|---|
KREBSBIO |
02 Jan 2025, 17:38:51 |
Certificate under SEBI (Depositories and Participants) Regulations, 2018 |
- |
KREBSBIO |
31 Dec 2024, 10:35:40 |
Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent |
- |
KREBSBIO |
31 Dec 2024, 10:33:25 |
Cessation |
- |
KREBSBIO |
30 Dec 2024, 14:02:49 |
Reply to Clarification- Financial results |
- |
KREBSBIO |
19 Dec 2024, 15:33:01 |
Trading Window-XBRL |
- |
NSE: KREBSBIO Corporate Governance
Name |
Symbol |
Timestamp |
Submission Date |
XBRL Document |
|---|---|---|---|---|
Krebs Biochemicals and Industries Limited |
KREBSBIO |
13 Jan 2025, 11:57:00 |
13 Jan 2025, 11:57:00 |
|
Krebs Biochemicals and Industries Limited |
KREBSBIO |
09 Oct 2024, 11:28:00 |
09 Oct 2024, 11:28:00 |
|
Krebs Biochemicals and Industries Limited |
KREBSBIO |
11 Jul 2024, 15:47:00 |
11 Jul 2024, 15:47:00 |
|
Krebs Biochemicals and Industries Limited |
KREBSBIO |
08 Jan 2024, 18:00:00 |
08 Jan 2024, 18:30:00 |
|
Krebs Biochemicals and Industries Limited |
KREBSBIO |
12 Oct 2023, 12:46:00 |
12 Oct 2023, 13:15:00 |
NSE: KREBSBIO Detailed Governance
Category |
Date of Birth |
Date of Initial Appointment |
DIN |
Director Name |
Status |
|---|---|---|---|---|---|
Chairperson Related To Promoters,Non-Executive Director |
08 Aug 1949 |
12 Oct 1992 |
00272977 |
RAVI RAVINDRANATH TAGORE |
Active |
Non-Executive Director |
15 Feb 1979 |
01 Feb 2009 |
01616152 |
AVINASH RAVI |
Active |
Independent Director |
31 Jul 1956 |
13 Aug 2014 |
00017081 |
VENKATA LAKSHMI PRASAD GUNDAPANENI |
Active |
Independent Director |
22 Mar 1949 |
12 Feb 2016 |
02166789 |
RAJ KAMAL PRASAD VERMA |
Active |
Independent Director |
21 Jun 1944 |
13 Aug 2015 |
07244464 |
SATISH KHEMCHAND KHIVSARA |
Active |
NSE: KREBSBIO Board Meetings
Purpose |
Symbol |
Industry |
ISIN |
Name |
Time |
|---|---|---|---|---|---|
Board Meeting Intimation |
KREBSBIO |
N/A |
INE268B01013 |
Krebs Biochemicals and Industries Limited |
28 Oct 2024, 11:44:56 |
Financial Results/Other business matters |
KREBSBIO |
N/A |
INE268B01013 |
Krebs Biochemicals and Industries Limited |
19 Jul 2024, 13:20:29 |
KREBS BIOCHEMICALS AND INDUSTRIES LIMITED has informed the Exchange about Board Meeting to be held on 21-May-2024 to inter-alia consider and approve the Audited Financial results of the Company for the Yearly ended March 2024 . |
KREBSBIO |
N/A |
INE268B01013 |
Krebs Biochemicals and Industries Limited |
08 May 2024, 11:04:46 |
Financial Results |
KREBSBIO |
N/A |
INE268B01013 |
Krebs Biochemicals and Industries Limited |
19 Jan 2024, 12:02:02 |
Financial Results |
KREBSBIO |
N/A |
INE268B01013 |
Krebs Biochemicals and Industries Limited |
18 Oct 2023, 18:36:03 |
NSE: KREBSBIO Event Calendar
Purpose |
Symbol |
Industry |
ISIN |
Name |
Time |
Description |
|---|---|---|---|---|---|---|
Financial Results/Other business matters |
KREBSBIO |
- |
INE268B01013 |
Krebs Biochemicals and Industries Limited |
28 Oct 2024, 00:00:00 |
To consider and approve the financial results for the period ended September 30, 2024 and other business matters |
Financial Results/Other business matters |
KREBSBIO |
- |
INE268B01013 |
Krebs Biochemicals and Industries Limited |
19 Jul 2024, 00:00:00 |
The Company has informed that the meeting of Board of Directors of the Company is schedule on 07/08/2024 inter alia to consider and approve Unaudited Financial Results for the quarter ended 30th June 2024. |
Financial Results |
KREBSBIO |
- |
INE268B01013 |
Krebs Biochemicals and Industries Limited |
08 May 2024, 00:00:00 |
To consider and approve the financial results for the period ended March 31, 2024 |
Financial Results |
KREBSBIO |
- |
INE268B01013 |
Krebs Biochemicals and Industries Limited |
19 Jan 2024, 00:00:00 |
To consider and approve the Unaudited Financial Results of the 3rd quarter and 9 months ended December 31, 2023 of the Financial year 2023-24. |
Financial Results |
KREBSBIO |
- |
INE268B01013 |
Krebs Biochemicals and Industries Limited |
18 Oct 2023, 00:00:00 |
To consider and approve the unaudited financial results for the period ended September 30, 2023 |
NSE: KREBSBIO Balance Sheet Data In (Cr)
| date | period_type | Ordinary Shares Number | Share Issued | Net Debt | Total Debt | Tangible Book Value | Invested Capital | Working Capital | Net Tangible Assets | Capital Lease Obligations | Common Stock Equity | Total Capitalization | Total Equity Gross Minority Interest | Stockholders Equity | Other Equity Interest | Retained Earnings | Additional Paid In Capital | Capital Stock | Common Stock | Total Liabilities Net Minority Interest | Total Non Current Liabilities Net Minority Interest | Other Non Current Liabilities | Preferred Securities Outside Stock Equity | Non Current Pension And Other Postretirement Benefit Plans | Tradeand Other Payables Non Current | Long Term Debt And Capital Lease Obligation | Long Term Capital Lease Obligation | Long Term Debt | Long Term Provisions | Current Liabilities | Other Current Liabilities | Current Debt And Capital Lease Obligation | Current Debt | Pensionand Other Post Retirement Benefit Plans Current | Current Provisions | Payables | Other Payable | Accounts Payable | Total Assets | Total Non Current Assets | Other Non Current Assets | Non Current Prepaid Assets | Investmentin Financial Assets | Goodwill And Other Intangible Assets | Other Intangible Assets | Net PPE | Accumulated Depreciation | Gross PPE | Construction In Progress | Other Properties | Machinery Furniture Equipment | Buildings And Improvements | Land And Improvements | Properties | Current Assets | Other Current Assets | Restricted Cash | Prepaid Assets | Inventory | Other Inventories | Finished Goods | Work In Process | Raw Materials | Other Receivables | Accounts Receivable | Allowance For Doubtful Accounts Receivable | Gross Accounts Receivable | Cash Cash Equivalents And Short Term Investments | Other Short Term Investments | Cash And Cash Equivalents | Cash Financial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-09-30T00:00:00 | quarterly | 21,560,586.00 | 21,560,586.00 | 2,044,240,000.00 | 2,045,682,000.00 | -1,325,598,000.00 | 744,194,000.00 | -775,059,000.00 | -1,325,598,000.00 | 0.00 | -1,301,488,000.00 | 307,512,000.00 | -1,301,488,000.00 | -1,301,488,000.00 | -1,517,094,000.00 | 0.00 | 0.00 | 215,606,000.00 | 215,606,000.00 | 3,153,537,000.00 | 2,116,405,000.00 | 450,000,000.00 | 0.00 | 0.00 | 0.00 | 1,609,000,000.00 | 0.00 | 1,609,000,000.00 | 30,502,000.00 | 1,037,132,000.00 | 258,831,000.00 | 436,682,000.00 | 436,682,000.00 | 0.00 | 17,060,000.00 | 174,522,000.00 | 0.00 | 174,522,000.00 | 1,852,049,000.00 | 1,589,976,000.00 | 67,574,000.00 | 0.00 | 26,433,000.00 | 24,110,000.00 | 24,110,000.00 | 1,471,859,000.00 | 0.00 | 1,471,859,000.00 | 6,586,000.00 | 1,465,273,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 262,073,000.00 | 47,097,000.00 | 0.00 | 0.00 | 77,267,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 25,654,000.00 | 0.00 | 0.00 | 112,055,000.00 | 110,613,000.00 | 1,442,000.00 | 0.00 |
| 2024-03-31T00:00:00 | quarterly | 21,560,586.00 | 21,560,586.00 | 1,936,069,000.00 | 2,386,760,000.00 | -1,217,199,000.00 | 744,593,000.00 | -443,917,000.00 | -1,217,199,000.00 | 450,000,000.00 | -1,192,167,000.00 | 642,833,000.00 | -1,192,167,000.00 | -1,192,167,000.00 | 3,938,000.00 | -2,702,395,000.00 | 1,180,176,000.00 | 215,606,000.00 | 215,606,000.00 | 2,973,914,000.00 | 2,355,575,000.00 | 450,000,000.00 | 0.00 | 30,502,000.00 | 40,073,000.00 | 2,285,000,000.00 | 450,000,000.00 | 1,835,000,000.00 | 4,941,000.00 | 618,339,000.00 | 178,666,000.00 | 101,760,000.00 | 101,760,000.00 | 10,619,000.00 | 6,192,000.00 | 327,294,000.00 | 137,594,000.00 | 189,700,000.00 | 1,781,747,000.00 | 1,607,325,000.00 | -4,000.00 | 37,541,000.00 | 25,408,000.00 | 25,032,000.00 | 25,032,000.00 | 1,497,394,000.00 | -1,603,355,000.00 | 3,100,749,000.00 | 4,385,000.00 | 218,544,000.00 | 2,120,611,000.00 | 273,022,000.00 | 484,187,000.00 | 0.00 | 174,422,000.00 | 25,921,000.00 | 683,000.00 | 26,139,000.00 | 97,964,000.00 | 0.00 | 15,110,000.00 | 51,180,000.00 | 31,674,000.00 | 29,911,000.00 | 19,034,000.00 | 0.00 | 0.00 | 691,000.00 | 30,129,000.00 | 691,000.00 | 691,000.00 |
| 2024-03-31T00:00:00 | annual | 21,560,586.00 | 21,560,586.00 | 1,936,069,000.00 | 2,386,760,000.00 | -1,217,199,000.00 | 744,593,000.00 | -443,917,000.00 | -1,217,199,000.00 | 450,000,000.00 | -1,192,167,000.00 | 642,833,000.00 | -1,192,167,000.00 | -1,192,167,000.00 | 3,938,000.00 | -2,702,395,000.00 | 1,180,176,000.00 | 215,606,000.00 | 215,606,000.00 | 2,973,914,000.00 | 2,355,575,000.00 | 450,000,000.00 | 0.00 | 30,502,000.00 | 40,073,000.00 | 2,285,000,000.00 | 450,000,000.00 | 1,835,000,000.00 | 4,941,000.00 | 618,339,000.00 | 178,666,000.00 | 101,760,000.00 | 101,760,000.00 | 10,619,000.00 | 6,192,000.00 | 327,294,000.00 | 137,594,000.00 | 189,700,000.00 | 1,781,747,000.00 | 1,607,325,000.00 | -4,000.00 | 37,541,000.00 | 25,408,000.00 | 25,032,000.00 | 25,032,000.00 | 1,497,394,000.00 | -1,603,355,000.00 | 3,100,749,000.00 | 4,385,000.00 | 218,544,000.00 | 2,120,611,000.00 | 273,022,000.00 | 484,187,000.00 | 0.00 | 174,422,000.00 | 25,921,000.00 | 683,000.00 | 26,139,000.00 | 97,964,000.00 | 0.00 | 15,110,000.00 | 51,180,000.00 | 31,674,000.00 | 29,911,000.00 | 19,034,000.00 | 0.00 | 0.00 | 691,000.00 | 30,129,000.00 | 691,000.00 | 691,000.00 |
| 2023-09-30T00:00:00 | quarterly | 21,560,586.00 | 21,560,586.00 | 1,877,423,000.00 | 1,878,206,000.00 | -1,109,616,000.00 | 794,541,000.00 | -389,389,000.00 | -1,109,616,000.00 | 0.00 | -1,083,665,000.00 | 696,335,000.00 | -1,083,665,000.00 | -1,083,665,000.00 | -1,299,271,000.00 | 0.00 | 0.00 | 215,606,000.00 | 215,606,000.00 | 2,864,940,000.00 | 2,311,377,000.00 | 449,997,000.00 | 0.00 | 25,962,000.00 | 0.00 | 1,780,000,000.00 | 0.00 | 1,780,000,000.00 | 3,066,000.00 | 553,563,000.00 | 148,922,000.00 | 98,206,000.00 | 98,206,000.00 | 17,483,000.00 | 11,722,000.00 | 166,835,000.00 | 0.00 | 166,835,000.00 | 1,781,275,000.00 | 1,617,102,000.00 | 55,631,000.00 | 0.00 | 24,396,000.00 | 25,951,000.00 | 25,951,000.00 | 1,511,124,000.00 | 0.00 | 1,511,124,000.00 | 1,946,000.00 | 1,509,178,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 164,174,000.00 | 22,699,000.00 | 0.00 | 0.00 | 111,465,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 9,633,000.00 | 0.00 | 0.00 | 20,377,000.00 | 19,594,000.00 | 783,000.00 | 0.00 |
| 2023-03-31T00:00:00 | quarterly | 21,560,586.00 | 21,560,586.00 | 1,833,529,000.00 | 2,283,704,000.00 | -1,021,493,000.00 | 839,081,000.00 | -330,438,000.00 | -1,021,493,000.00 | 450,000,000.00 | -994,623,000.00 | 737,842,000.00 | -994,623,000.00 | -994,623,000.00 | 3,938,000.00 | -2,504,851,000.00 | 1,180,176,000.00 | 215,606,000.00 | 215,606,000.00 | 2,744,440,000.00 | 2,253,393,000.00 | -1,000.00 | 0.00 | 25,962,000.00 | 44,967,000.00 | 2,182,465,000.00 | 450,000,000.00 | 1,732,465,000.00 | 3,066,000.00 | 491,047,000.00 | 122,929,000.00 | 101,239,000.00 | 101,239,000.00 | 12,621,000.00 | 7,467,000.00 | 254,258,000.00 | 101,452,000.00 | 152,806,000.00 | 1,749,817,000.00 | 1,589,208,000.00 | -3,000.00 | 35,889,000.00 | 23,756,000.00 | 26,870,000.00 | 26,870,000.00 | 1,490,468,000.00 | -1,537,529,000.00 | 3,027,997,000.00 | 25,782,000.00 | 214,319,000.00 | 2,037,336,000.00 | 266,373,000.00 | 484,187,000.00 | 0.00 | 160,609,000.00 | -1,000.00 | 683,000.00 | 32,422,000.00 | 119,456,000.00 | -1,000.00 | 13,129,000.00 | 63,854,000.00 | 42,474,000.00 | 2,622,000.00 | 5,252,000.00 | 0.00 | 0.00 | 175,000.00 | 2,859,000.00 | 175,000.00 | 175,000.00 |
| 2023-03-31T00:00:00 | annual | 21,560,586.00 | 21,560,586.00 | 1,833,529,000.00 | 2,283,704,000.00 | -1,021,493,000.00 | 839,081,000.00 | -330,438,000.00 | -1,021,493,000.00 | 450,000,000.00 | -994,623,000.00 | 737,842,000.00 | -994,623,000.00 | -994,623,000.00 | 3,938,000.00 | -2,504,851,000.00 | 1,180,176,000.00 | 215,606,000.00 | 215,606,000.00 | 2,744,440,000.00 | 2,253,393,000.00 | -1,000.00 | 0.00 | 25,962,000.00 | 44,967,000.00 | 2,182,465,000.00 | 450,000,000.00 | 1,732,465,000.00 | 3,066,000.00 | 491,047,000.00 | 122,929,000.00 | 101,239,000.00 | 101,239,000.00 | 12,621,000.00 | 7,467,000.00 | 254,258,000.00 | 101,452,000.00 | 152,806,000.00 | 1,749,817,000.00 | 1,589,208,000.00 | -3,000.00 | 35,889,000.00 | 23,756,000.00 | 26,870,000.00 | 26,870,000.00 | 1,490,468,000.00 | -1,537,529,000.00 | 3,027,997,000.00 | 25,782,000.00 | 214,319,000.00 | 2,037,336,000.00 | 266,373,000.00 | 484,187,000.00 | 0.00 | 160,609,000.00 | -1,000.00 | 683,000.00 | 32,422,000.00 | 119,456,000.00 | -1,000.00 | 13,129,000.00 | 63,854,000.00 | 42,474,000.00 | 2,622,000.00 | 5,252,000.00 | 0.00 | 0.00 | 175,000.00 | 2,859,000.00 | 175,000.00 | 175,000.00 |
| 2022-03-31T00:00:00 | annual | 21,560,586.00 | 21,560,586.00 | 1,430,670,000.00 | 1,880,994,000.00 | -779,641,000.00 | 680,062,000.00 | -425,708,000.00 | -779,641,000.00 | 450,000,000.00 | -750,932,000.00 | 578,368,000.00 | -750,932,000.00 | -750,932,000.00 | 3,938,000.00 | -2,261,160,000.00 | 1,180,176,000.00 | 215,606,000.00 | 215,606,000.00 | 2,648,989,000.00 | 1,868,349,000.00 | 450,000,000.00 | 1,300,000,000.00 | 26,336,000.00 | 62,713,000.00 | 1,779,300,000.00 | 450,000,000.00 | 1,329,300,000.00 | 3,016,000.00 | 780,640,000.00 | 148,072,000.00 | 101,694,000.00 | 101,694,000.00 | 11,653,000.00 | 16,410,000.00 | 502,811,000.00 | 123,747,000.00 | 379,064,000.00 | 1,898,057,000.00 | 1,543,124,000.00 | 1,000.00 | 35,120,000.00 | 22,988,000.00 | 28,709,000.00 | 28,709,000.00 | 1,449,252,000.00 | -1,474,484,000.00 | 2,923,736,000.00 | 72,402,000.00 | 204,344,000.00 | 1,905,883,000.00 | 256,920,000.00 | 484,187,000.00 | 0.00 | 354,932,000.00 | -2,000.00 | 683,000.00 | 88,567,000.00 | 255,626,000.00 | -1,000.00 | 16,487,000.00 | 119,206,000.00 | 119,934,000.00 | 969,000.00 | 8,765,000.00 | 0.00 | 8,765,000.00 | 324,000.00 | 2,108,000.00 | 324,000.00 | 324,000.00 |
| 2021-03-31T00:00:00 | annual | 19,620,586.00 | 19,620,586.00 | 805,457,000.00 | 1,261,382,000.00 | -462,424,000.00 | 384,053,000.00 | -267,748,000.00 | -462,424,000.00 | 450,000,000.00 | -427,329,000.00 | 278,135,000.00 | -427,329,000.00 | -427,329,000.00 | 45,648,000.00 | -1,812,427,000.00 | 1,032,736,000.00 | 196,206,000.00 | 196,206,000.00 | 2,019,532,000.00 | 1,537,608,000.00 | 450,000,000.00 | 300,000,000.00 | 25,637,000.00 | 56,507,000.00 | 1,155,464,000.00 | 450,000,000.00 | 705,464,000.00 | 5,009,000.00 | 481,924,000.00 | 70,409,000.00 | 105,918,000.00 | 105,918,000.00 | 14,937,000.00 | 8,245,000.00 | 290,660,000.00 | 82,893,000.00 | 207,767,000.00 | 1,592,203,000.00 | 1,378,027,000.00 | 56,962,000.00 | 34,562,000.00 | 22,430,000.00 | 35,095,000.00 | 35,095,000.00 | 1,282,087,000.00 | -1,417,904,000.00 | 2,699,991,000.00 | 119,437,000.00 | 258,818,000.00 | 1,615,757,000.00 | 221,792,000.00 | 484,187,000.00 | 0.00 | 214,176,000.00 | -1,000.00 | 1,183,000.00 | 37,301,000.00 | 166,004,000.00 | 0.00 | 13,928,000.00 | 66,417,000.00 | 85,659,000.00 | 766,000.00 | 2,998,000.00 | 0.00 | 2,998,000.00 | 5,925,000.00 | 3,667,000.00 | 5,925,000.00 | 5,925,000.00 |
| 2020-03-31T00:00:00 | annual | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 300,000,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -464,000.00 | 2,484,000.00 | 0.00 | 0.00 | 0.00 | 0.00 |
NSE: KREBSBIO Cash Flow Data In (Cr)
| date | period_type | Free Cash Flow | Issuance Of Capital Stock | Capital Expenditure | End Cash Position | Other Cash Adjustment Outside Changein Cash | Beginning Cash Position | Changes In Cash | Financing Cash Flow | Net Other Financing Charges | Interest Paid Cff | Net Common Stock Issuance | Common Stock Issuance | Net Issuance Payments Of Debt | Net Long Term Debt Issuance | Investing Cash Flow | Net Other Investing Changes | Net Intangibles Purchase And Sale | Net PPE Purchase And Sale | Operating Cash Flow | Change In Working Capital | Change In Other Current Liabilities | Change In Other Current Assets | Change In Payable | Change In Inventory | Change In Receivables | Other Non Cash Items | Provisionand Write Offof Assets | Depreciation And Amortization | Amortization Cash Flow | Depreciation | Net Income From Continuing Operations |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31T00:00:00 | annual | -50,233,000.00 | 0.00 | -73,273,000.00 | 1,374,000.00 | 2,000.00 | 858,000.00 | 514,000.00 | 55,641,000.00 | 0.00 | -46,894,000.00 | 0.00 | 0.00 | 102,535,000.00 | 102,535,000.00 | -78,167,000.00 | -4,894,000.00 | 0.00 | -73,273,000.00 | 23,040,000.00 | 101,486,000.00 | 92,401,000.00 | -33,517,000.00 | 36,894,000.00 | 21,492,000.00 | -13,782,000.00 | 46,894,000.00 | 4,280,000.00 | 67,663,000.00 | 1,838,000.00 | 65,825,000.00 | -197,284,000.00 |
| 2023-03-31T00:00:00 | annual | -355,836,000.00 | 0.00 | -108,704,000.00 | 858,000.00 | 1,000.00 | 1,006,000.00 | -149,000.00 | 373,433,000.00 | 0.00 | -29,732,000.00 | 0.00 | 0.00 | 403,165,000.00 | 403,165,000.00 | -126,450,000.00 | -17,746,000.00 | 0.00 | -108,704,000.00 | -247,132,000.00 | -98,383,000.00 | -64,303,000.00 | 51,527,000.00 | -226,258,000.00 | 136,170,000.00 | 3,513,000.00 | 29,732,000.00 | 2,854,000.00 | 65,585,000.00 | 1,839,000.00 | 63,746,000.00 | -246,919,000.00 |
| 2022-03-31T00:00:00 | annual | -407,363,000.00 | 0.00 | -235,201,000.00 | 1,006,000.00 | 0.00 | 7,107,000.00 | -6,101,000.00 | 395,056,000.00 | 1,000.00 | -53,910,000.00 | 125,130,000.00 | 0.00 | 323,835,000.00 | 323,835,000.00 | -228,995,000.00 | 6,206,000.00 | 0.00 | -235,201,000.00 | -172,162,000.00 | 158,996,000.00 | 130,703,000.00 | -44,331,000.00 | 171,297,000.00 | -89,622,000.00 | -5,767,000.00 | 53,910,000.00 | -2,765,000.00 | 62,966,000.00 | 6,386,000.00 | 56,580,000.00 | -445,268,000.00 |
| 2021-03-31T00:00:00 | annual | -400,812,000.00 | 0.00 | -255,064,000.00 | 7,107,000.00 | 0.00 | 1,743,000.00 | 5,364,000.00 | 376,605,000.00 | 0.00 | -62,790,000.00 | 104,489,000.00 | 0.00 | 334,906,000.00 | 334,906,000.00 | -225,493,000.00 | 29,571,000.00 | 0.00 | -255,064,000.00 | -145,748,000.00 | 21,077,000.00 | 89,727,000.00 | -27,986,000.00 | -18,713,000.00 | -16,049,000.00 | -977,000.00 | 62,790,000.00 | 2,731,000.00 | 51,239,000.00 | 2,602,000.00 | 48,637,000.00 | -283,586,000.00 |
| 2020-03-31T00:00:00 | annual | 0.00 | 76,540,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 76,540,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
NSE: KREBSBIO Income Statement Data In (Cr)
| date | period_type | Tax Effect Of Unusual Items | Tax Rate For Calcs | Normalized EBITDA | Total Unusual Items | Total Unusual Items Excluding Goodwill | Net Income From Continuing Operation Net Minority Interest | Reconciled Depreciation | Reconciled Cost Of Revenue | EBITDA | EBIT | Net Interest Income | Interest Expense | Interest Income | Normalized Income | Net Income From Continuing And Discontinued Operation | Total Expenses | Rent Expense Supplemental | Diluted Average Shares | Basic Average Shares | Diluted EPS | Basic EPS | Diluted NI Availto Com Stockholders | Net Income Common Stockholders | Otherunder Preferred Stock Dividend | Net Income | Net Income Including Noncontrolling Interests | Net Income Discontinuous Operations | Net Income Continuous Operations | Tax Provision | Pretax Income | Other Non Operating Income Expenses | Special Income Charges | Other Special Charges | Write Off | Net Non Operating Interest Income Expense | Total Other Finance Cost | Interest Expense Non Operating | Interest Income Non Operating | Operating Income | Operating Expense | Other Operating Expenses | Depreciation And Amortization In Income Statement | Amortization | Depreciation Income Statement | Selling General And Administration | Selling And Marketing Expense | General And Administrative Expense | Rent And Landing Fees | Gross Profit | Cost Of Revenue | Total Revenue | Operating Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31T00:00:00 | annual | 0.00 | 0.00 | -8.28 | 0.00 | 0.00 | -19.73 | 6.77 | 31.15 | -8.28 | -15.04 | -4.53 | 4.69 | 0.16 | -19.73 | -19.73 | 65.62 | 0.58 | 2.16 | 2.16 | 0.00 | 0.00 | -19.73 | -19.73 | 0.00 | -19.73 | -19.73 | 0.00 | -19.73 | 0.00 | -19.73 | 0.45 | 0.00 | 0.00 | 0.00 | -4.53 | 0.00 | 4.69 | 0.16 | -15.20 | 34.47 | 5.90 | 6.77 | 0.18 | 6.58 | 0.60 | 0.00 | 0.60 | 0.58 | 19.27 | 31.15 | 50.42 | 50.42 |
| 2023-03-31T00:00:00 | annual | 0.00 | 0.00 | -15.16 | 0.00 | 0.00 | -24.69 | 6.56 | 42.35 | -15.16 | -21.72 | -2.75 | 2.97 | 0.22 | -24.69 | -24.69 | 74.07 | 0.69 | 2.16 | 2.16 | 0.00 | 0.00 | -24.69 | -24.69 | 0.00 | -24.69 | -24.69 | 0.00 | -24.69 | 0.00 | -24.69 | 0.62 | 0.00 | 0.00 | 0.00 | -2.75 | 0.00 | 2.97 | 0.22 | -21.94 | 31.72 | 4.88 | 6.56 | 0.18 | 6.37 | 0.86 | 0.00 | 0.86 | 0.69 | 9.78 | 42.35 | 52.13 | 52.13 |
| 2022-03-31T00:00:00 | annual | 0.00 | 0.00 | -32.85 | 0.00 | 0.00 | -44.53 | 6.30 | 65.47 | -32.85 | -39.14 | -5.03 | 5.38 | 0.36 | -44.53 | -44.53 | 99.20 | 0.68 | 2.16 | 2.16 | 0.00 | 0.00 | -44.53 | -44.53 | 0.00 | -44.53 | -44.53 | 0.00 | -44.53 | 0.00 | -44.53 | 1.02 | 0.00 | 0.18 | 0.00 | -5.03 | 0.01 | 5.38 | 0.36 | -39.49 | 33.73 | 7.47 | 6.30 | 0.64 | 5.66 | 1.14 | 0.00 | 1.14 | 0.68 | -5.76 | 65.47 | 59.70 | 59.70 |
| 2021-03-31T00:00:00 | annual | 0.00 | 0.00 | -16.84 | -0.13 | -0.13 | -28.36 | 5.12 | 52.23 | -16.96 | -22.09 | -6.21 | 6.27 | 0.07 | -28.23 | -28.36 | 61.65 | 0.94 | 1.96 | 1.96 | 0.00 | 0.00 | -28.36 | -28.36 | 0.00 | -28.36 | -28.36 | 0.00 | -28.36 | 0.00 | -28.36 | 1.02 | -0.13 | 0.05 | 0.08 | -6.21 | 0.01 | 6.27 | 0.07 | -23.04 | 9.42 | 2.05 | 5.12 | 0.26 | 4.86 | 0.68 | 0.00 | 0.67 | 0.31 | -13.63 | 52.23 | 38.61 | 38.61 |
| 2020-03-31T00:00:00 | annual | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.12 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.10 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
FII & DII Data (In Cr)
| Date | FII Gross Purchase | FII Gross Sales | FII Net Purchase / Sales | DII Gross Purchase | DII Gross Sales | DII Net Purchase / Sales |
|---|---|---|---|---|---|---|
| 2025-02-03 | 12,505.92 | 16,464.29 | -3,958.37 | 19,319.48 | 16,611.25 | 2,708.23 |
| 2025-01-30 | 10,513.63 | 15,096.58 | -4,582.95 | 13,934.35 | 11,768.46 | 2,165.89 |
| 2025-01-29 | 7,644.40 | 10,230.83 | -2,586.43 | 12,871.38 | 11,078.67 | 1,792.71 |
| 2025-01-27 | 9,488.57 | 14,504.03 | -5,015.46 | 16,503.43 | 9,861.28 | 6,642.15 |
| 2025-01-24 | 11,230.47 | 13,988.96 | -2,758.49 | 12,835.41 | 10,433.10 | 2,402.31 |
| 2025-01-23 | 13,316.55 | 18,779.07 | -5,462.52 | 14,412.73 | 10,700.18 | 3,712.55 |
| 2025-01-22 | 12,936.64 | 16,962.89 | -4,026.25 | 15,437.18 | 11,796.96 | 3,640.22 |
Piotroski F-Score
7/9
0
1
2
3
4
5
6
7
8
9
Key Metrics
EPS
-10.1
P/E
N/A
P/B
N/A
Dividend Yield
N/A
Market Cap
229.27 Cr.
Face Value
-55.294
Book Value
-55.294
ROE
-37.11%
EBITDA Growth
-7.79 Cr.
Debt/Equity
N/A
Short Term
Subscribe to unlock this feature
Medium Term
Subscribe to unlock this feature
Long Term
Subscribe to unlock this feature
Yearly Stock Performance Heatmap
Latest Updates
Ashoka Buildcon Arm Signs Rs 1,391 Crore Pact With NHAI
Ashoka Buildcon Ltd. announced on Monday, via an exchange filing, that its wholly owned subsidiary, Ashoka Bowaichandi Guskara Road Pvt Ltd., has exec...
Budget 2025: Rahul Bajoria On Addressing Income Growth And Consumption Trends
"However, discretionary, high-value consumption is taking a step back due to income growth settling at high single digits." Over the past fe...
FPIs Stay Net Sellers, Sell Stocks Worth Rs 2,575 Crore
Foreign portfolio investors stayed net sellers for the second straight session on Monday and sold stocks worth approximately Rs 2,575.1 crore, accordi...
Budget 2025: AMFI Seeks Tax Policy Reforms To Drive Mutual Fund Investments In 15-Point Proposal
The Association of Mutual Funds of India on Monday released a 15-point proposal for Union Budget 2025-26 requesting changes in tax policies that are i...
Apple iPhone SE 4: Price To Features, 11 Things You Need To Know
iPhone 16e (Not iPhone SE 4): If recent reports are to be believed, Apple may discontinue the SE label and rename iPhone SE 4 as iPhone 16e. Most Affo...
Rupee Closed Weaker Against The US Dollar
The rupee weakened by five paise to close at 85.83 against the US dollar. The Indian rupee had declined to a fresh low against the US dollar during th...
Table Space Founder Amit Banerji Dies Of Heart Attack At Age Of 45
Amit Banerji, the founder, chairman and chief executive officer of managed workspace provider Table Space, died after suffering from a heart attack, r...
War Fatigue, Economic Breakdown Or Pro-West? Why Syria's Al-Sharaa Is Seen Soft On Israel
The strategic positions have been used by Israeli forces to carry out hundreds of strikes to destroy Syria's military infrastructure. In 2011, be...
Popular Questions
What is the Market Cap of krebsbio?
The market capitalization of Krebs Biochemicals & Industries Limited is ₹229 Cr as of 05 Feb 2025.
What are the PE and PB ratios of Krebs Biochemicals & Industries Limited?
The PE and PB ratios of Krebs Biochemicals & Industries Limited are Not Available and Not Available respectively as of 05 Feb 2025.
What is the 52 Week High of Krebs Biochemicals & Industries Limited?
The 52-week high of Krebs Biochemicals & Industries Limited is ₹129.07 as of 05 Feb 2025.
What is the 52 Week Low of Krebs Biochemicals & Industries Limited?
The 52-week low of Krebs Biochemicals & Industries Limited is ₹60.35 as of 05 Feb 2025.
What are the earnings per share (EPS) for Krebs Biochemicals & Industries Limited?
The Earnings Per Share (EPS) of Krebs Biochemicals & Industries Limited is ₹-10.1 as per the most recent quarterly results available on Fincept.
What is the ROE (Return on Equity) of Krebs Biochemicals & Industries Limited?
The Return on Equity (ROE) of Krebs Biochemicals & Industries Limited is -37.11% as per the most recent financial year data. Explore more on Fincept.